Respiratory distress is one of the most common and frightening symptoms of children with life-limiting conditions. Because treatment of the underlying cause is frequently impossible or insufficient, in many children, symptomatic treatment is warranted. The purpose of this study was to describe the circumstances of the use of intranasal fentanyl in an acute attack of respiratory distress (AARD) in children receiving palliative care, as well as to describe outcomes and adverse events after its use.
Children and adolescents treated in a pediatric palliative unit or attended by a specialized home care team between 2010 and 2016 were included in this study. A retrospective chart review was conducted of those who were treated with intranasal fentanyl for an AARD.
During the study period 16 children (0.5–18.6 years) with various life-limiting conditions were treated with intranasal fentanyl for AARD. In total, 70 AARDs were analyzed. In 74% of all AARDs, a single dose of intranasal fentanyl was used. Frequent causes for an AARD were excessive secretions and acute respiratory infection. The median starting dose of intranasal fentanyl was 1.5 μg/kg body weight. Labored breathing (96%), tachypnea (79%) and related suffering (97%) improved after treatment. An adverse event occurred in one child.
Intranasal fentanyl may be a safe and effective medication for the treatment of acute attacks of respiratory distress in children with life-limiting conditions. However, prospective studies with larger sample sizes and a control group are needed to validate these findings.
von Lutzau P, Otto M, Hechler T, Metzing S, Wolfe J, Zernikow B. Children dying from cancer: parents' perspectives on symptoms, quality of life, characteristics of death, and end-of-life decisions. J Palliat Care 2012, 28(4):274–281.
Wolfe J, Hammel JF, Edwards KE, Duncan J, Comeau M, Breyer J, Aldridge SA, Grier HE, Berde C, Dussel V, et al. Easing of suffering in children with cancer at the end of life: is care changing? J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008;26(10):1717–23. CrossRef
Drake R, Frost J, Collins JJ. The symptoms of dying children. J Pain Symptom Manag. 2003;26(1):594–603. CrossRef
Garske D, Schmidt P, Hasan C, Wager J, Zernikow B. Palliativversorgung auf der pädiatrischen Palliativstation “Lichtblicke” – Eine retrospektive Studie. Zeitschrift für Palliativmedizin. 2016;17(06):302–7. CrossRef
Collins JJ, Byrnes ME, Dunkel IJ, Lapin J, Nadel T, Thaler HT, Polyak T, Rapkin B, Portenoy RK. The measurement of symptoms in children with cancer. J Pain Symptom Manag. 2000;19(5):363–77. CrossRef
Pieper L, Zernikow B, Drake R, Frosch M, Printz M, Wager J. Dyspnea in children with life-threatening and life-limiting complex chronic conditions. J Palliat Med. 2018;
American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med. 1999;159(1):321–40. CrossRef
Leach RM. Palliative care in non-malignant, end-stage respiratory disease. In: Hanks G, Cherny NI, Christakis NA, Fallon M, Kaasa S, Portenoy RK, editors. Oxford textbook of palliative medicine. Edn. New York, NY: Oxford University Press; 2010. p. 1231–67.
Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, Calverley PM, Gift AG, Harver A, Lareau SC, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–52. CrossRefPubMedPubMedCentral
Bausewein C, Booth S, Gysels M, Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. The Cochrane database of systematic reviews 2008(2):Cd005623.
Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ (Clinical research ed). 2003;327(7414):523–8. CrossRef
Sitte T, Bausewein C. Intranasal fentanyl for episodic breathlessness. J Pain Symptom Manag. 2008;36(6):e3–6. CrossRef
Sitte T. Nasal application of fentanyl citrate as symptom control against breathlessness in palliative care--overview and case report. Wien. Med. Wochenschr (1946). 2009;159(23–24):566–70. CrossRef
Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc LJ, Le Guen M, Fischler M, Devillier P. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther 2012, 134(3):366–379.
Crellin D, Ling RX, Babl FE. Does the standard intravenous solution of fentanyl (50 microg/mL) administered intranasally have analgesic efficacy? Emerg. Med. Australas. : EMA. 2010;22(1):62–7. PubMed
Freye E, Levy JV, Braun D. Effervescent morphine results in faster relief of breakthrough pain in patients compared to immediate release morphine sulfate tablet. Pain practice : the official journal of World Institute of Pain. 2007;7(4):324–31. CrossRef
Murphy A, O'Sullivan R, Wakai A, Grant TS, Barrett MJ, Cronin J, McCoy SC, Hom J, Kandamany N. Intranasal fentanyl for the management of acute pain in children. The Cochrane database of systematic reviews 2014(10):Cd009942.
Simon ST, Koskeroglu P, Gaertner J, Voltz R. Fentanyl for the relief of refractory breathlessness: a systematic review. J Pain Symptom Manag. 2013;46(6):874–86. CrossRef
Harlos MS, Stenekes S, Lambert D, Hohl C, Chochinov HM. Intranasal fentanyl in the palliative care of newborns and infants. J Pain Symptom Manag. 2013;46(2):265–74. CrossRef
Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag. 2006;31(1):58–69. CrossRef
Borland ML, Jacobs I, Geelhoed G. Intranasal fentanyl reduces acute pain in children in the emergency department: a safety and efficacy study. Emergency medicine (Fremantle, WA). 2002;14(3):275–80. CrossRef
Borland ML, Clark LJ, Esson A. Comparative review of the clinical use of intranasal fentanyl versus morphine in a paediatric emergency department. Emerg. Med. Australas. : EMA. 2008;20(6):515–20. PubMed
Finkel JC, Cohen IT, Hannallah RS, Patel KM, Kim MS, Hummer KA, Choi SS, Pena M, Schreiber SB, Zalzal G. The effect of intranasal fentanyl on the emergence characteristics after sevoflurane anesthesia in children undergoing surgery for bilateral myringotomy tube placement. Anesth Analg. 2001;92(5):1164–8. CrossRefPubMed
Holdgate A, Cao A, Lo KM. The implementation of intranasal fentanyl for children in a mixed adult and pediatric emergency department reduces time to analgesic administration. Acad Emerg Med Off J Soc Acad Emerg Med. 2010;17(2):214–7. CrossRef
Younge PA, Nicol MF, Kendall JM, Harrington AP. A prospective randomized pilot comparison of intranasal fentanyl and intramuscular morphine for analgesia in children presenting to the emergency department with clinical fractures. Emerg Med. 1999;11:90–4. CrossRef
- Intranasal fentanyl for respiratory distress in children and adolescents with life-limiting conditions
- BioMed Central
Neu im Fachgebiet AINS
Meistgelesene Bücher aus dem Fachgebiet AINS
Mail Icon II